SPARC Q2 revenue falls 39%; net loss narrows 29%
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited Q2 and half-year results. Consolidated Q2 revenue fell 39% to Rs 7.86 crore, while net loss narrowed 29% to Rs 75.85 crore. Half-year revenue fell 41% to Rs 17.50 crore and net loss narrowed 37% to Rs 127.72 crore. Operating cash outflow was Rs 115.87 crore, cash was Rs 0.94 crore, and equity was negative Rs 344.64 crore. Promoter support allows continued operations.
Liabilities above assets, falling revenue and heavy cash burn raise funding risk and may pressure the stock; promoter support offers some relief.